share_log

上海医药(601607.SH):雷贝拉唑钠肠溶片通过仿制药一致性评价

Shanghai Pharmaceutical (601607.SH): Rabeprazole sodium enteric tablets passed generic drug consistency evaluation

Gelonghui Finance ·  Apr 10 04:28

Gelonghui, April 10 | Shanghai Pharmaceutical (601607.SH) announced that its wholly-owned subsidiary Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd. received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration for rabeprazole sodium enteric tablets. The drug passed the generic drug consistency evaluation. Rabeprazole sodium enteric tablets are mainly used to treat gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, and Zhuo-Ai syndrome. It is used as an adjunct to treat patients with gastric ulcer or duodenal ulcer to eradicate Helicobacter pylori, by eISaiCo. , Ltd. R&D, first listed in Japan in 1997. In September 2023, Shanghai Pharmaceutical Xinyi submitted an application to the State Drug Administration for the generic consistency evaluation of this drug and it was accepted.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment